An expanding role for mTOR in cancer

Trends in Molecular Medicine

Volumn 11, Issue 8, 2005, Pages 353-361

  Guertin, David A ^a   Sabatini, David M ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG;

CAENORHABDITIS ELEGANS; CANCER GROWTH; CANCER THERAPY; CELL GROWTH; DROSOPHILA; ENZYME ACTIVATION; EVALUATION; GENE CONTROL; GENE TARGETING; HUMAN; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 23144467910     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2005.06.007     Document Type: Article

References (110)

1. M.A. Bjornsti, and P.J. Houghton The TOR pathway: a target for cancer therapy Nat. Rev. Cancer 4 2004 335 348
2. S. Chan Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer Br. J. Cancer 91 2004 1420 1424
3. D.D. Sarbassov Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
4. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
5. M.P. Wymann Phosphoinositide 3-kinase signalling - which way to target? Trends Pharmacol. Sci. 24 2003 366 376
6. B. Stiles PTENless means more Dev. Biol. 273 2004 175 184
7. I. Sansal, and W.R. Sellers The biology and clinical relevance of the PTEN tumor suppressor pathway J. Clin. Oncol. 22 2004 2954 2963
8. J.E. Thompson, and C.B. Thompson Putting the rap on Akt J. Clin. Oncol. 22 2004 4217 4226
9. D.P. Brazil Advances in protein kinase B signalling: AKTion on multiple fronts Trends Biochem. Sci. 29 2004 233 242
10. R.M. Easton Role for Akt3/protein kinase Bγ in attainment of normal brain size Mol. Cell. Biol. 25 2005 1869 1878
11. X.D. Peng Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2 Genes Dev. 17 2003 1352 1365
12. R.S. Garofalo Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB β J. Clin. Invest. 112 2003 197 208
13. T. Shioi Akt/protein kinase B promotes organ growth in transgenic mice Mol. Cell. Biol. 22 2002 2799 2809
14. R.L. Tuttle Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα Nat. Med. 7 2001 1133 1137
15. W.S. Chen Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene Genes Dev. 15 2001 2203 2208
16. H. Cho Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice J. Biol. Chem. 276 2001 38349 38352
17. H. Cho Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β) Science 292 2001 1728 1731
18. E.L. Whiteman Role of Akt/protein kinase B in metabolism Trends Endocrinol. Metab. 13 2002 444 451
19. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev. 18 2004 1926 1945
20. J.C. Rathmell Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival Mol. Cell. Biol. 23 2003 7315 7328
21. D.R. Plas Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology J. Biol. Chem. 276 2001 12041 12048
22. D. DeFeo-Jones Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members Mol. Cancer Ther. 4 2005 271 279
23. J.E. Dancey Molecular targeting: PI3 kinase pathway Ann. Oncol. 15 Suppl. 4 2004 iv233 iv239
24. E.K. Rowinsky Targeting the molecular target of rapamycin (mTOR) Curr. Opin. Oncol. 16 2004 564 575
25. S. Vignot mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Oncol. 16 2005 525 537
26. D-H. Kim mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2002 163 175
27. K. Hara Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 110 2002 177 189
28. R. Loewith Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol. Cell 10 2002 457 468
29. D.D. Sarbassov Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr. Biol. 14 2004 1296 1302
30. E. Jacinto Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive Nat. Cell Biol. 6 2004 1122 1128
31. D.H. Kim GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR Mol. Cell 11 2003 895 904
32. D.A. Guertin Growth control through the mTOR network M.N. Hall Cell Growth: Control of Cell Size 2004 Cold Spring Harbor Laboratory Press 193 234
33. M.S. Neshat Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc. Natl. Acad. Sci. U. S. A. 98 2001 10314 10319
34. +/- mice Proc. Natl. Acad. Sci. U. S. A. 98 2001 10320 10325
35. M. Aoki A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt Proc. Natl. Acad. Sci. U. S. A. 98 2001 136 141
36. Y. Shi Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res. 62 2002 5027 5034
37. D.C. Fingar, and J. Blenis Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Oncogene 23 2004 3151 3171
38. s6k gene reveals a small mouse phenotype and a new functional S6 kinase EMBO J. 17 1998 6649 6659
39. I.H. Park Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin J. Biol. Chem. 277 2002 31423 31429
40. M. Pende Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice Nature 408 2000 994 997
41. S.H. Um Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity Nature 431 2004 200 205
42. -/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway Mol. Cell. Biol. 24 2004 3112 3124
43. Y. Mamane eIF4E - from translation to transformation Oncogene 23 2004 3172 3179
44. E.I. Surace Functional significance of S6K overexpression in meningioma progression Ann. Neurol. 56 2004 295 298
45. M. Barlund Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis J. Natl. Cancer Inst. 92 2000 1252 1259
46. M.K. Holz, and J. Blenis Identification of S6K1 as a novel mTOR-phosphorylating kinase J. Biol. Chem 2005 10.1074/jbc.M504045200 (http://www.jbc.org/ )
47. G.G. Chiang, and R.T. Abraham Phosphorylation of mTOR at Ser-2448 is mediated by p70S6 kinase J. Biol. Chem 2005 10.1074/jbc.M501707200 (http://www.jbc.org/ )
48. E.M. Smith The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses J. Biol. Chem. 280 2005 18717 18727
49. X. Long Rheb binds and regulates the mTOR kinase Curr. Biol. 15 2005 702 713
50. X. Long Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency J. Biol. Chem. 280 2005 23433 23436
51. K. Inoki TSC2 mediates cellular energy response to control cell growth and survival Cell 115 2003 577 590
52. Z. Luo AMPK, the metabolic syndrome and cancer Trends Pharmacol. Sci. 26 2005 69 76
53. J.M. Lizcano LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1 EMBO J. 23 2004 833 843
54. R.J. Shaw The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell 6 2004 91 99
55. R.J. Shaw The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress Proc. Natl. Acad. Sci. U. S. A. 101 2004 3329 3335
56. M.N. Corradetti Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome Genes Dev. 18 2004 1533 1538
57. J.H. Reiling, and E. Hafen The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila Genes Dev. 18 2004 2879 2892
58. J. Brugarolas Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex Genes Dev. 18 2004 2893 2904
59. G.L. Semenza Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 3 2003 721 732
60. C.C. Hudson Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin Mol. Cell. Biol. 22 2002 7004 7014
61. J.B. Brugarolas TSC2 regulates VEGF through mTOR-dependent and -independent pathways Cancer Cell 4 2003 147 158
62. K. Inoki Dysregulation of the TSC-mTOR pathway in human disease Nat. Genet. 37 2005 19 24
63. A.R. Tee, and J. Blenis mTOR, translational control and human disease Semin. Cell Dev. Biol. 16 2005 29 37
64. C. Eng PTEN: one gene, many syndromes Hum. Mutat. 22 2003 183 198
65. L.S. Harrington Restraining PI3K: mTOR signalling goes back to the membrane Trends Biochem. Sci. 30 2005 35 42
66. L.S. Harrington The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J. Cell Biol. 166 2004 213 223
67. O.J. Shah Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr. Biol. 14 2004 1650 1656
68. T. Radimerski Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling Genes Dev. 16 2002 2627 2632
69. H. Zhang Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR J. Clin. Invest. 112 2003 1223 1233
70. A. Takano Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin Mol. Cell. Biol. 21 2001 5050 5062
71. F. Tremblay, and A. Marette Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells J. Biol. Chem. 276 2001 38052 38060
72. J. Dong, and D. Pan Tsc2 is not a critical target of Akt during normal Drosophila development Genes Dev. 18 2004 2479 2484
73. A. Mora PDK1, the master regulator of AGC kinase signal transduction Semin. Cell Dev. Biol. 15 2004 161 170
74. A. Balendran PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2 Curr. Biol. 9 1999 393 404
75. S. Persad Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343 J. Biol. Chem. 276 2001 27462 27469
76. A. Toker, and A.C. Newton Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site J. Biol. Chem. 275 2000 8271 8274
77. J. Feng Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase J. Biol. Chem. 279 2004 41189 41196
78. M.Y. Chen A novel cytosolic regulator, Pianissimo, is required for chemoattractant receptor and G protein-mediated activation of the 12 transmembrane domain adenylyl cyclase in Dictyostelium Genes Dev. 11 1997 3218 3231
79. R. Meili Chemoattractant-mediated transient activation and membrane localization of Akt/PKB is required for efficient chemotaxis to cAMP in Dictyostelium EMBO J. 18 1999 2092 2105
80. P. Kapahi Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway Curr. Biol. 14 2004 885 890
81. K. Jia The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span Development 131 2004 3897 3906
82. T. Vellai Genetics: influence of TOR kinase on lifespan in C. elegans Nature 426 2003 620
83. A.L. Edinger Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells Cancer Res. 63 2003 8451 8460
84. L. Cheatham Structural and functional analysis of pp70S6k Proc. Natl. Acad. Sci. U. S. A. 92 1995 11696 11700
85. Q.P. Weng Multiple independent inputs are required for activation of the p70 S6 kinase Mol. Cell. Biol. 15 1995 2333 2340
86. S.M. Ali, and D.M. Sabatini Structure of S6K1 determines if raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site J. Biol. Chem. 280 2005 19445 19448
87. W.C. Noh Determinants of rapamycin sensitivity in breast cancer cells Clin. Cancer Res. 10 2004 1013 1023
88. CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin Cancer Res. 61 2001 3373 3381
89. W. Lieberthal Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells Am. J. Physiol. Renal Physiol. 281 2001 F693 F706
90. H.L. Kenerson Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors Cancer Res. 62 2002 5645 5650
91. K.N. Thimmaiah Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways Cancer Res. 63 2003 364 374
92. KIP1 expression Blood 101 2003 1439 1445
93. Cip1 Mol. Cell 11 2003 1491 1501
94. D. Ruggero The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis Nat. Med. 10 2004 484 486
95. H.G. Wendel Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 428 2004 332 337
96. K.E. Hentges FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse Proc. Natl. Acad. Sci. U. S. A. 98 2001 13796 13801
97. M. Murakami mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells Mol. Cell. Biol. 24 2004 6710 6718
98. Y.G. Gangloff Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development Mol. Cell. Biol. 24 2004 9508 9516
99. C. Kenyon The plasticity of aging: insights from long-lived mutants Cell 120 2005 449 460
100. V.P. Krymskaya, and J.M. Shipley Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation Am. J. Respir. Cell Mol. Biol. 28 2003 546 550
101. T.W. Abel Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway J. Neuropathol. Exp. Neurol. 64 2005 341 349
102. 2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis Hum. Mol. Genet. 10 2001 1215 1220
103. kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies Virchows Arch. 444 2004 509 517
104. J. Li PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
105. A. Bellacosa Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas Int. J. Cancer 64 1995 280 285
106. B.P. Zhou, and M.C. Hung Dysregulation of cellular signaling by HER2/neu in breast cancer Semin. Oncol. 30 Suppl. 16 2003 38 48
107. C.J. Barnes, and R. Kumar Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets Cancer Metastasis Rev. 22 2003 301 307
108. J.S. Aveyard Somatic mutation of PTEN in bladder carcinoma Br. J. Cancer 80 1999 904 908
109. L. Shayesteh PIK3CA is implicated as an oncogene in ovarian cancer Nat. Genet. 21 1999 99 102
110. B.K. Rasheed Molecular pathogenesis of malignant gliomas Curr. Opin. Oncol. 11 1999 162 167